Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $4.28 Million Stock Position in Cencora, Inc. (NYSE:COR)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA reduced its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 54.5% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 15,029 shares of the company's stock after selling 17,998 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Cencora were worth $4,279,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. IFP Advisors Inc grew its holdings in shares of Cencora by 105.0% during the fourth quarter. IFP Advisors Inc now owns 1,810 shares of the company's stock worth $410,000 after purchasing an additional 927 shares during the last quarter. Crestwood Advisors Group LLC raised its holdings in shares of Cencora by 18.3% in the fourth quarter. Crestwood Advisors Group LLC now owns 1,256 shares of the company's stock valued at $282,000 after buying an additional 194 shares during the last quarter. FourThought Financial Partners LLC acquired a new position in Cencora during the 4th quarter worth about $215,000. Advisor OS LLC grew its holdings in Cencora by 55.8% during the 4th quarter. Advisor OS LLC now owns 2,243 shares of the company's stock worth $504,000 after acquiring an additional 803 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in Cencora by 0.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 15,051 shares of the company's stock worth $3,382,000 after acquiring an additional 120 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Up 1.5%

Shares of Cencora stock opened at $296.70 on Friday. The business has a fifty day simple moving average of $289.70 and a 200 day simple moving average of $264.56. The stock has a market cap of $57.51 billion, a PE ratio of 34.42, a price-to-earnings-growth ratio of 1.45 and a beta of 0.58. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company's revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $3.80 earnings per share. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.74%. Cencora's dividend payout ratio is 25.52%.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman now directly owns 311,913 shares in the company, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock valued at $9,812,296 in the last quarter. Company insiders own 10.80% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on COR shares. Robert W. Baird upped their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Friday, April 11th. Wells Fargo & Company raised Cencora from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $274.00 to $337.00 in a report on Tuesday, June 3rd. UBS Group increased their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research report on Tuesday, April 29th. Finally, Citigroup lifted their target price on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $306.91.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.